Introduction
Dysregulation of mineral homeostasis due to failing kidney function leads to decreased renal phosphate excretion, elevated fibroblast growth factor 23 level, and reduced synthesis of calcitriol. These changes lead to consistent secretion of parathyroid hormone (PTH) contributing to the development of parathyroid hyperplasia and secondary hyperparathyroidism (SHPT) in end-stage renal disease. SHPT with elevated calcium and phosphate levels contributes to the development of renal osteodystrophy, erythropoietin resistance, vascular calcification, and left ventricular hypertrophy. These clinical features are strongly associated with increased morbidity and mortality in dialytic end-stage renal disease population. [1] [2] [3] [4] It is therefore critical to maintain optimal level of PTH in these patients. However, because of the complicated problems of lowering PTH with simultaneously controlling imbalanced serum levels of calcium and phosphate, traditional therapies of phosphate binders and vitamin D analogues for managing SHPT have all too often led to clinical problems, including hypercalcemia, One of the newer treatment options for SHPT is cinacalcet which increases the sensitivity of the calcium-sensing receptor (CaSR) on the parathyroid gland cells to extracellular calcium, 6 resulting in a decreased calcium set point and circulating PTH levels. [6] [7] [8] The cinacalcet treatment resulted in 41% of SHPT patients achieving PTH and Ca × P levels recommended by the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines 9 whereas fewer than 10% of the patients treated with phosphate binders and vitamin D analogs reached optimal control. 10 Moreover, cinacalcet reduced the risk of parathyroidectomy by 91%. 11 Cinacalcet treatment is effective to the extent that it can be utilized as an alternative to surgical intervention in some patients. 12, 13 Despite the overall response to cinacalcet being promising in a number of clinical trials, [14] [15] [16] the therapeutic efficacy has a significant inter-individual variability of 12.1%-46% PTH reduction, representing drug resistance. [17] [18] [19] [20] [21] The factors associated with the drug resistance include delayed therapy, persistent hyperphosphatemia, nodular hyperplasia, 22 and reduced expression of CaSR and vitamin D receptor (VDR). [23] [24] [25] In particular, genetic polymorphisms affecting CaSR and VDR expression have been considered as factors for drug resistance. The genetic polymorphism of CASR Arg990Gly (c.2968A  G, rs1042636) was associated with different cinacalcet response. 26 Several other studies [27] [28] [29] on CASR presented the possible association of CASR rs1042636 and rs2221266 polymorphisms with PTH level difference. VDR gene polymorphisms of rs7975232 (Apa 1), rs731236 (Taq 1), and rs1544410 (Bsm 1) were also associated with PTH regulation. [30] [31] [32] These studies presented the clinical importance of genetic polymorphisms in PTH regulation. However, the results available so far show limited evidence for genetic polymorphisms associated with cinacalcet response involving a small number of patients and not including phosphate and bone regulation-related genes in PTH homeostasis. Thus, we aimed to evaluate the frequency of variants of study genes related to PTH regulation and the association between SNPs and haplotypes of genes and cinacalcet response in Korean SHPT patients on dialysis.
Methods

study subjects
Study patients were selected from a tertiary university hospital in Seoul, Korea, between June 2011 and July 2014. Patients with a diagnosis of SHPT based on intact parathyroid hormone (iPTH) 300 pg/mL were included in this study.
The patients were over 18 years and have been treated by cinacalcet for more than 3 months. All these patients were on either hemodialysis or peritoneal dialysis, receiving optimal medical therapy in the form of dietary restriction, phosphate binders, or vitamin D sterols. The main exclusion criteria were serious concomitant hepatic disease, active cancers, or taking strong CYP3A4 inhibitors, such as itraconazole, clarithromycin, diltiazem, and verapamil.
The study complies with the Helsinki Declaration and was approved by the Ethics Committee of the Seoul National University Hospital (IRB #: H-1408-082-604). Written informed consents were obtained from all patients.
Data collection
Demographic information on the cause of chronic kidney disease (CKD), mode and duration of dialysis, concomitant drugs, and biochemical parameter levels of serum calcium, phosphorus, alkaline phosphatase, iPTH, creatinine, estimated glomerular filtration rate using Modification of Diet in Renal Disease equation, albumin, and hemoglobin at the start and during 3 months of cinacalcet treatment was obtained. Responders and nonresponders were grouped by their serum iPTH changes. Nonresponders were grouped as the patients whose iPTH levels increased even after 3 months of cinacalcet treatment. 33, 34 Otherwise, those patients whose iPTH values showed any reduction during the period of 3-month cinacalcet treatment were defined as responders.
Serum calcium and phosphate levels were measured by standard methods; iPTH was measured using a doubleantibody immunoradiometric assay for the quantitative determination of intact biological chain of 84 amino acids of PTH in human serum (ELSA PTH, Cisbio Bioassays, Codolet, France). Serum calcium was reported as albumin corrected values throughout this research.
genotype selection and analysis
Twenty-five SNPs in nine genes which are previously known as related to calcium, phosphate, and bone metabolism were selected from the results of previous literatures and databases. Of these genes, CASR [26] [27] [28] [29] [35] [36] [37] and VDR [30] [31] [32] 38, 39 
Results
Patient data
A total of 70 dialysis patients with SHPT were included in the biochemical parameter analysis. Baseline characteristics were well balanced between the responders and nonresponders except for baseline calcium levels (P=0.001). The baseline iPTH for 68 patients was 622 (300-1,493) pg/mL versus 601 (316-1,183) pg/mL (P=0.375) for responders versus nonresponders, respectively. The parathyroid gland hyperplasia or adenomatous state did not differ between two groups (P=0.726). The amount of vitamin D (calcitriol or paricalcitol) taken by the patients (P=0.116) and the number of patients on phosphate binders and vitamin D analogues were not different between the two groups (P=0.116 and P=1.000, respectively) ( Table 1 ). The maintenance dose of cinacalcet ranged from 12.5 to 100 mg per day, depending on patient's status. The dose was higher in nonresponders: responders 25 (12.5-75) mg/day versus nonresponders 50 (25-100) mg/day (P0.001).
Biochemical parameter changes
The biochemical parameter changes between baseline and 3-month treatment are summarized in Table 2 . Cinacalcet significantly reduced serum iPTH levels in 53 responders. The percent iPTH changes between baseline and 3-month treatment were -42.29 (-97.41 to 9.23) % versus 6.16 (0.90 to 45.25) % in responders versus nonresponders, respectively (P0.001). At 3-month treatment, 39.6% (21/53) of responders had an iPTH level below 300 pg/mL, the level recommended by the K/DOQI guidelines. 9 The percent change of serum calcium concentration at 3-month treatment was -5. 
Frequency analysis of genetic polymorphisms
The loci, allele, and minor allele frequency (MAF) results are summarized in Table 3 . The observed MAFs in CASR rs1042636 and rs1802757 were 45.8% and 35.8%, respectively. VDR rs7975232 (Apa 1) and rs1544410 (bsm 1) were 16.0% and 6.3%, respectively, whereas rs2228570 (Fok 1) was 38.2%.
association with cinacalcet response association of 24 snPs with iPTh
The association of 24 SNPs with cinacalcet response was evaluated ( Table 4 ). The chi-square test showed that CASR rs1042636 had a significant difference in genotype frequencies between responder and nonresponders (P=0.036) but the MAF was not significant (P=0.075). The chi-square test also proved that CASR rs1042636 had a significant association with cinacalcet response (odds ratio [OR]: 0.267, P=0.035) in the dominant genetic model ( 
association of CASR haplotypes with iPTh
The distribution of haplotypes was constructed for three genes and assessed for the association with the cinacalcet response. Linkage disequilibrium structures were designated by the D' value shown in Figure 1 . Each of CASR, VDR, and ALPL genes included one haplotype block. The correlation coefficient (r 2 ) between rs1042636 and rs1802757, rs1042636 and rs10190, and rs1802757 and rs10190 was CASR, VDR, FGFR1, KL, RGS14, SLC34A1, ALPL (Table 6 ).
association of CASR genotypes with biochemical parameters
The associations between CASR genotypes and biochemical parameter changes were evaluated in 70 patients. The parameters showed that 3-month cinacalcet treatment lowered overall levels of serum calcium, -6. (Table S2) .
Discussion
In this study, the genotype frequencies of the SNPs related to PTH regulation and the association with cinacalcet response were evaluated. The observed MAFs in CASR rs1042636 and rs1802757 were double the reported frequency in HapMap 54 whereas VDR rs7975232 (Apa I) and rs1544410 (bsm I) showed a lower frequency than that of HapMap. The rs2228570 (Fok 1) showed a similar frequency. Furthermore, the novel findings of our study are that genetic polymorphisms of CASR rs1802757 besides rs1042636 and haplotypes of rs1042636, rs10190, and rs1802757 were significantly associated with cinacalcet response. The gain of function nonsynonymous SNP of rs1042636, which is 55 and showed the consistent result with the previous study by Rothe et al. 26 The study suggested that an Asian dialysis patient carrying a homozygous (G/G) variant of CASR rs1042636 showed significant iPTH reduction after 2-month cinacalcet treatment compared to another six patients having different genotypes. Several other studies [27] [28] [29] on CASR also presented the possible association of CASR rs1042636 with PTH level difference. However, the functionality of rs1802757 which is located in 3′ untranslated region (UTR) has not been well documented. We can assume that the rs1802757 influences the microRNAs which have the binding sites within 3′UTR, and can decrease gene expression of various mRNAs. 56, 57 Other studies presented that CaSR activated by calcimimetics decreased PTH-mRNA stability through the posttranslational modification of the PTH-mRNA binding protein AUF1. 58 The rs1802757 can be investigated further via similar mechanism. In particular, the SNPs of rs1042636 and rs1802757 and haplotypes of GCC and ATT occurred at high frequencies of 45.8%, 35.9%, 52.9%, and 37.5%, respectively; in our result, the impact of these variants should not be negligible among Asians.
The regulation of PTH secretion and synthesis involves a multitude of pathways. 59 However, in our study, the SNPs of genes other than CASR seemed not to correlate with cinacalcet response. Studies of Casr and Vdr knockout mice can explain part of our results. VDR-deficient mice which developed severe SHPT could be corrected by stabilizing serum calcium concentrations, 60 whereas CaSR-deficient mice with SHPT were not corrected by elevated serum calcium and vitamin D levels and normal serum phosphorus, 61 
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Jeong et al which demonstrates that CaSR is the major regulator of PTH secretion and bone abnormalities. 62 Thus, other genes related to phosphate and bone metabolism do not have much effect on the PTH regulation by cinacalcet.
The maximum dose of cinacalcet approved in Korea is 100 mg/day and the higher titration dose did not control the PTH level in nonresponders. Previous studies suggested that early response to cinacalcet determined the effectiveness of cinacalcet treatment. 63, 64 Therefore, our study can suggest that CKD patients who carry T allele of rs1802757 and/or ATT haplotype of rs1042646, rs10190 and rs1802757 have high risk of cinacalcet treatment failure and might be candidates for the parathyroidectomy. There have been pharmacoeconomic issues about the indefinite long-term cinacalcet treatment versus one-time surgery. The research in the 5 European countries by Iannazzo et al 65 proved that cinacalcet treatment was beneficial when compared to the standard therapy of vitamin D analogues in cost-effectiveness and cost utility model compared to standard therapy of vitamin D analogs. Komaba et al 66 presented that cinacalcet was cost-effective in 99.9% of the Monte Carlo simulations in parathyroidectomy ineligible patients, but only 0.9% of the simulations in parathyroidectomy eligible patients. Thus, nonresponders to cinacalcet treatment can have minimal cost-effectiveness compared to surgery in economic issues.
SHPT patients are highly vulnerable to cardiovascular morbidity and mortality and neither parathyroidectomy 67 nor cinacalcet 68 reduces the risk of death or major cardiovascular events in SHPT patients undergoing dialysis. Therefore, the [69] [70] [71] [72] however, the noticeable PTH decrease followed by hypocalcaemia and hyperphosphatemia brought about the avoidance of cinacalcet prescription in CKD predialysis patients. [73] [74] [75] Since our findings in this study provided a potential target for the investigation of cinacalcet nonresponder group who have high possibility of parathyroidectomy or refractory SHPT, CASR SNPs may be useful biomarkers to administer cinacalcet in early stage of CKD patients to attain the individualized medical treatment of SHPT.
The main factors of cinacalcet resistance after several months or years of therapy are severely enlarged parathyroid gland (1 cm), nodular hyperplasia, 22, 76, 77 and the downregulation of CaSR and VDR by uremic status which is resulted by inadequate dialysis. 78 However, the parathyroid hyperplasia did not affect the cinacalcet nonresponsiveness in our shortterm study as in previous studies. 79, 80 The dose of vitamin D was not different between two groups and findings from the study by Block et al 81 presented that cinacalcet reduced PTH levels regardless of whether the vitamin D doses were increased, decreased, or unchanged. We performed multiple testing by Bonferroni correction and false discovery rate test. The result turned out that the association of rs1042636 or rs1802757 with PTH change was not significant. However, neither of these methods take into account the correlation of SNPs due to linkage disequilibrium, which tags the genetic variation across gene regions. Our result showed that the three SNPs of CASR, five SNPs of VDR, and three SNPs of ALPL comprise one haploblock each, representing that the SNPs are not independent and highly correlated. Thus, we rather not reflect the multiple testing in the results.
Our study has several limitations as follows. The first, 70 Korean patients are relatively small for genetic association study and diverse ethnic factors could not be considered. This limitation should warrant further large-scale studies to replicate and confirm our findings. The second, the included patients were on either hemodialysis or peritoneal dialysis; the Kt/V(K urea ×T d /V urea ) value which indicates the dialysis adequacy is not recirpocally conversed between two modalities, so the influence of dialysis could not be evaluated in our study. The third, we focused on the 3-month treatment of cinacalcet, and the result of long-term follow-up study on the mineral bone disease and cardiovascular disease could not be assessed. The last, most patients were on either phosphate binders or vitamin D analogs and the proportion of patients on either drug was not different between two groups, but the possible impact of different amount of concomitant calcium intake cannot be ruled out.
Conclusion
We obtained supporting evidence for an association between cinacalcet response and CASR polymorphisms. We performed a comprehensive search for SNPs within genes associated with PTH regulations to find the precise frequencies and association with cinacalcet response in 70 dialytic SHPT patients for the first time in Korea. CASR SNPs rs1802757, rs1042636, and haplotypes of rs1042636, rs10190, and rs1802757 were significantly associated with cinacalcet response variance. 
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